ArticleCancer imaging : the official publication of the International Cancer Imaging Society2017
Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 29 citations in OpenAlex.
- Lymph node dissection based on 18F-PSMA PET/CT during radical prostatectomy for intermediate and high risk prostate cancer: interim results of a prospective, randomized study.Prostate cancer and prostatic diseases · 2026Trial
- Article
- Comparative Analysis ofAdvances in radiation oncology · 2025Article
- Development and first-in-human study of PSMA-targeted PET tracers with improved pharmacokinetic properties.European journal of nuclear medicine and molecular imaging · 2024Article
- Article
- Comprehensive literature review of oral and intravenous contrast-enhanced PET/CT: a step forward?Frontiers in medicine · 2024Review
- PSMA PET imaging in the diagnosis and management of prostate cancer.Abdominal radiology (New York) · 2023Review
- The future of PSMA PET and WB MRI as next-generation imaging tools in prostate cancer.Nature reviews. Urology · 2022Review
- Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Prospective intra-individual blinded comparison of [European journal of nuclear medicine and molecular imaging · 2022Article
- Intra-patient comparison of physiologicCancer imaging : the official publication of the International Cancer Imaging Society · 2021Article
- False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial.European journal of nuclear medicine and molecular imaging · 2021Article
- The utility of pharmacological and radiological interventions to optimize diagnostic information from PET/CT.Cancer imaging : the official publication of the International Cancer Imaging Society · 2020Review
- Combined Intravenous Urogram and 68Ga-PSMA PET/ CT for Improved Staging and Restaging of Prostate Cancer.Journal of clinical imaging science · 2020Article
- The role of MRI for detection and staging of radio- and focal therapy-recurrent prostate cancer.World journal of urology · 2019Review
- Intra-individual comparison ofCancer imaging : the official publication of the International Cancer Imaging Society · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background
methodsA retrospective review of PSMA PET/CT-U preformed on 57 consecutive patients with prostate cancer. Fifty mL of IV contrast was administered 10 min (range 8-15) before the CT component of a combined PET/CT study, acquired approximately 60 min (range 40-85) after administration of 166 MBq (range 91-246) of
resultsOverall 50 PSMA PET/CT-U studies were performed for BCR and 7 for PS. Median PSA with BCR and PS were 2.0 ± 11.4 ng/ml (0.06-57.3 ng/ml) and 18 ± 35.3 ng/ml (6.8-100 ng/ml), respectively. The median Gleason-score for both groups was 7 (range 6-10). In BCR group, PSMA PET was reported positive in 36 (72%) patients, CT-U in 11(22%) patients and PET/CT-U in 33 (66%) patients. In PS group, PSMA PET detected the primary site in all seven patients, of which one patient with metastatic nodal disease had negative CT finding. Of 40 equivocal foci (27/57 patients) on PET, 11 foci (10/57 patients, 17.5%) were localized to enhanced urine on PET/CT-U, hence considered of potential benefit in interpretation. Of those, 3 foci (3 patients) were solitary sites of activity on PSMA imaging including two local and one nodal site and 4 foci (3 patients) were in different nodal fields.
conclusionsPET/CT-U protocol is a practical approach and may assist in interpretation of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.